← Back to Calendar

elebsiran

Alnylam / Roche · $ALNY
Priority Review Breakthrough Therapy NDA
PDUFA Date
November 10, 2026
Time Remaining
211 days
Review Type
Priority (6 mo)
90%
Baseline PoA
NDA priority review approval rate
Based on FDA historical approval rates by submission type (2015–2025)
Dynamic PoA
Coming soon
xAI Sentiment

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$322.11 +42.35%
+$95.83 today
Day: $317.53 – $328.89
Market Cap
N/A
Shares out: 133.43M
Float: 132.07M
52-Week Range
$225.84
$495.55
Current price is at 36% of 52-week range
Avg Volume
1.31M
Beta
0.38
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $ALNY catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Hepatitis B virus (HBV) — functional cure combination therapy

Key Notes

RNAi therapy in combination with imdusiran targeting functional cure for chronic HBV.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar